Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$9.46

-0.34 (-3.47%)

08:20
11/06/18
11/06
08:20
11/06/18
08:20

Iovance Biotherapeutics to present new data on Phase 2 C-144-01 trial at SITC

Iovance Biotherapeutics announced that a presentation of new data from the ongoing Phase 2 lifileucel metastatic melanoma trial, or C-144-01, will occur at the Society for Immunotherapy of Cancer, or SITC. The most common treatment emergent adverse events observed in this cohort to date include chills, febrile neutropenia, anaemia, decreased platelet count, pyrexia, and hypophosphataemia. Two grade 5 events occurred. One was deemed not related to lifileucel by the investigator and the other possibly related.

  • 06

    Nov

IOVA Iovance Biotherapeutics
$9.46

-0.34 (-3.47%)

09/13/18
JEFF
09/13/18
NO CHANGE
Target $31
JEFF
Buy
Feedback on Moffitt TIL study appears positive, says Jefferies
Jefferies analyst Biren Amin hosted a call with an oncologist at Moffitt Cancer Center to review the initial data from this first non-small cell lung cancer tumor infiltrating lymphocytes study. The doctor highlighted the large unmet need in NSCLC patients who failed to respond to anti-PD-1 therapy and feels the 100% disease control rate achieved in the first eight refractory patients to nivo is promising, Amin tells investors in a research note. Further, the oncologist believes the limited duration of response could improve in a second NSCLC study incorporating key "biomarkers," the analyst points out. Amin believes Iovance Biotherapeutics could incorporate some of these key learnings into its two Phase I/II NSCLC studies. The analyst keeps a Buy rating on Iovance with a $31 price target.
09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.

TODAY'S FREE FLY STORIES

GLD

SPDR Gold Shares

$126.70

1.89 (1.51%)

19:46
02/19/19
02/19
19:46
02/19/19
19:46
Hot Stocks
SPDR Gold Shares holdings fall to 792.45MT from 793.03MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

18:25
02/19/19
02/19
18:25
02/19/19
18:25
Conference/Events
CLSA technology analyst to hold an analyst/industry conference call »

Technology Sales…

VICL

Vical

$1.01

(0.00%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Hot Stocks
Breaking Hot Stocks news story on Vical »

Vical resumes trade down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$57.39

0.5847 (1.03%)

, MDLZ

Mondelez

$48.10

-0.07 (-0.15%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Periodicals
Kellogg, Mondelez stock up on snacks as Brexit looms, Reuters reports »

With Brexit on the…

K

Kellogg

$57.39

0.5847 (1.03%)

MDLZ

Mondelez

$48.10

-0.07 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 03

    Mar

  • 06

    Mar

  • 28

    May

OMI

Owens & Minor

$7.94

0.25 (3.25%)

18:19
02/19/19
02/19
18:19
02/19/19
18:19
Earnings
Owens & Minor guides initial FY19 EPS 60c-75c, consensus $1.02 »

"2019 is about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$7.94

0.25 (3.25%)

18:17
02/19/19
02/19
18:17
02/19/19
18:17
Earnings
Owens & Minor reports Q4 adjusted EPS 9c, consensus 13c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

USAC

USA Compression

$15.61

0.61 (4.07%)

18:15
02/19/19
02/19
18:15
02/19/19
18:15
Recommendations
USA Compression analyst commentary  »

USA Compression Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

DK

Delek US

$34.87

0.025 (0.07%)

18:04
02/19/19
02/19
18:04
02/19/19
18:04
Hot Stocks
Delek US raises dividend 3.8% to 27c »

Delek US announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DK

Delek US

$34.87

0.025 (0.07%)

18:03
02/19/19
02/19
18:03
02/19/19
18:03
Earnings
Delek US reports Q4 adjusted EPS $1.59, consensus $1.25 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DKL

Delek Logistics

$30.39

0.58 (1.95%)

18:01
02/19/19
02/19
18:01
02/19/19
18:01
Earnings
Delek Logistics reports Q4 EPS 58c, consensus 74c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$7.94

0.25 (3.25%)

, TMO

Thermo Fisher

$250.77

-1.615 (-0.64%)

17:49
02/19/19
02/19
17:49
02/19/19
17:49
Hot Stocks
Owens & Minor names Ed Pesicka President and CEO »

Owens & Minor (OMI)…

OMI

Owens & Minor

$7.94

0.25 (3.25%)

TMO

Thermo Fisher

$250.77

-1.615 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

VICL

Vical

$1.01

(0.00%)

17:49
02/19/19
02/19
17:49
02/19/19
17:49
Hot Stocks
Breaking Hot Stocks news story on Vical »

Vical to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.01

(0.00%)

17:48
02/19/19
02/19
17:48
02/19/19
17:48
Earnings
Vical reports Q4 EPS (17c), two estimates (17c) »

Vical had cash and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.